Clinical trials: Atopic Dermatitis/Eczema
Atopic Dermatitis
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneously using devices for injection.
- Trial name
- ROCKET-Outpost (NCT06224192)
- Testing
- Rocatinlimab Prefilled Syringe, Rocatinlimab AI
- Where
- 47 sites in United States, Canada and 2 more
- Volunteers
- 151 people
- Sponsor
- Amgen
Dermatologic Disease
A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone
One of the most frequent skin conditions is atopic dermatitis (AD), characterized by its pruritic inflammation effect. Where the prevalence of AD increased in the last three decades by two or three folds worldwide, especially in…
- Trial name
- NCT05607901
- Testing
- Tacrolimus ointment, Hydrocortisone 1% cream
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University
Atopic Dermatitis
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
- Trial name
- ROCKET-ASCEND (NCT05882877)
- Testing
- Rocatinlimab
- Where
- 547 sites in United States, Argentina and 40 more
- Volunteers
- 2,621 people
- Sponsor
- Amgen
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To demonstrate the superiority of the investigational medicinal product (IMP; 0.3% OPA-15406 ointment, 1% OPA-15406 ointment, or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in…
- Trial name
- NCT03911401
- Testing
- 0.3% OPA-15406, 1% OPA-15406
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis, Eczema
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADorable-1 (NCT05559359)
- Testing
- Lebrikizumab, Topical Corticosteroid (TCS)
- Where
- 85 sites in United States, Argentina and 10 more
- Volunteers
- 377 people
- Sponsor
- Eli Lilly and Company
Atopic Eczema
A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema
A 4 week, open label, multi-centre (GP setting), post market clinical follow-up study with Doublebase Once in patients of any age and any severity of atopic eczema.
- Trial name
- NCT06453512
- Testing
- Doublebase Once
- Where
- United Kingdom
- Volunteers
- 65 people
- Sponsor
- Dermal Laboratories Ltd
Atopic Dermatitis
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
- Trial name
- ADjoin (NCT04392154)
- Testing
- Lebrikizumab
- Where
- 321 sites in United States, Australia and 14 more
- Volunteers
- 1,153 people
- Sponsor
- Eli Lilly and Company
Eczema, Asthma
The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants
This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and…
- Conditions
- Eczema, Asthma, Allergy;Food
- Trial name
- PEBBLES (NCT03667651)
- Testing
- EpiCeram
- Where
- 4 sites in Australia
- Volunteers
- 760 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Atopic Dermatitis
Study of 0417 Ointment in the Treatment of Atopic Dermatitis
The aim of this trial is to assess the efficacy of 0417 Ointment in the Treatment of Atopic Dermatitis. Treatment medication will be administered as follows: Apply a thin layer of ointment to affected skin areas twice daily and…
- Trial name
- NCT01139450
- Testing
- 0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%
- Where
- United States
- Volunteers
- 899 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Asthma, Asthma in Children
Allergy, Asthma, and Atopic Eczema in Finland
The summary is available at --> https://www.finnatopy.fi/summary
- Conditions
- Asthma, Asthma in Children, Allergy, Rhinitis, Allergic
- Trial name
- FinnATOPY (NCT06330974)
- Testing
- No intervention, No Intervention: Observational Cohort
- Where
- Finland
- Volunteers
- 1,600,000 people
- Sponsor
- Tampere University
Atopic Dermatitis
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of…
- Trial name
- NCT04146363
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Australia and 8 more
- Volunteers
- 424 people
- Sponsor
- Eli Lilly and Company
Allergic Contact Dermatitis
Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents
The objective of the study was to evaluate the diagnostic performance and safety of T.R.U.E. Test allergens in pediatric subjects aged 6-17 years old.
- Trial name
- NCT01797562
- Testing
- Panels 1.3, 2.2 and 3.2 experimental allergens
- Where
- 4 sites in United States
- Volunteers
- 116 people
- Sponsor
- Allerderm
Atopic Dermatitis (Eczema)
The Effects of an L-histidine-Based Supplement, Eczema Topical, and Unscented Soap on Children With Eczema
The purpose of this study is to examine the effects of 2 dietary supplements containing the amino acid, L-histidine, alongside a plant-biotech topical product, and an unscented bar soap on 2 age groups of children with mild to…
- Trial name
- NCT07670676
- Testing
- Powder Supplement + Topical Oil + Unscented Soap, Gummy Supplement + Topical Lotion + Unscented Soap
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Codex Labs Corporation
Atopic Dermatitis
Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis
A phase 1 single center study in which omalizumab is dosed normally (according to the product insert) in subjects with atopic dermatitis.
- Trial name
- OXAD (NCT01678092)
- Testing
- omalizumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Stanford University
Atopic Dermatitis
Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis
Atopic dermatitis (AD), commonly known as eczema, is a chronic skin condition that causes itchy, red, and scaly patches on the skin.
- Trial name
- NCT07437534
- Testing
- Crisaborole 2% Topical Application Ointment [EUCRISA, tacrolimus 0.1%
- Where
- Pakistan
- Volunteers
- 148 people
- Sponsor
- Hayat Abad Medical Complex, Peshawar
Atopic Dermatitis
The Role of Confocal Microscopy in Estimating Dupilumab Treatment Response for Moderate/Severe Atopic Dermatitis
Atopic dermatitis (AD) is recognized as the most prevalent chronic inflammatory skin disease across all age groups. The introduction of reflectance confocal microscopy (RCM) signifies a substantial leap forward in the…
- Trial name
- NCT07098000
- Where
- Argentina
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Atopic Dermatitis
A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- UP-TAINED (NCT05139836)
- Where
- 125 sites in Germany
- Volunteers
- 634 people
- Sponsor
- AbbVie
Atopic Dermatitis
Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.
- Trial name
- NCT03826901
- Testing
- delgocitinib
- Where
- 16 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)
Primary Objective: To evaluate safety (4 weeks) Secondary Objectives: To evaluate the long-term safety (12 weeks) To evaluate the efficacy To characterize the pharmacokinetic profile
- Trial name
- NCT01244230
- Testing
- fexofenadine/Allegra (M016455)
- Where
- 13 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Sanofi
Atopic Dermatitis
Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis
The objective of this pilot double-blind study was to evaluate the efficacy and the safety of Broncho-Vaxom 1 capsule (3.5 mg) per day for 9 months compared to placebo on the evolution of the disease in children suffering from…
- Trial name
- NCT03047954
- Testing
- Broncho-Vaxom
- Volunteers
- 179 people
- Sponsor
- Vifor Pharma